Head and neck cancer trial pulled before it even started
NCT ID NCT06804850
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study was designed to see if adding low-dose radiotherapy to a combination of targeted therapy (Afatinib) and immunotherapy (Tislelizumab) before surgery could improve outcomes for people with resectable head and neck cancer. The trial was withdrawn before enrolling any participants, so no data were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tislelizumab (immunotherapy), Afatinib (targeted therapy), and low-dose radiotherapy
- What this could lead to
- If it had worked, this could have pointed toward a more effective pre-surgery treatment for head and neck cancer, potentially improving tumor shrinkage before surgery.
- What could go wrong
- The trial was withdrawn before any participants were enrolled, so no results are available. It is unknown whether the combination would have been safe or effective.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can tailored nutrition boost recovery from head and neck surgery?
- Can less radiation be safer for throat cancer?
- Can a scan tell who needs more surgery after head and neck cancer?